Aprepitant

Form: Oral capsules, Injection (IV)

Strength: Capsule (80 mg, 125 mg); Injection (IV):150 mg/3 mL

Reference Brands: Emend®(US & EU)

Category: Oncology Cancer Care

Aprepitant 80 mg and 125 mg Capsules are essential in managing chemotherapy-induced nausea and vomiting (CINV). Available under the brand name Emend® in both oral capsule and intravenous injection (150 mg/3 mL) formulations, Aprepitant is a neurokinin-1 receptor antagonist used in combination with other antiemetic agents. Approved in both the U.S. and EU, it effectively prevents acute and delayed nausea and vomiting caused by chemotherapy treatments, particularly those with high emetogenic potential. Aprepitant plays a critical role in oncology B2B portfolios focused on supportive cancer care, improving patient quality of life during treatment.